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ABSTRACT
Substituted anthranilic acid and piperazines were used as building blocks to prepare two libraries of compounds, with the aim
being that they would exhibit biochemical activity as small molecule kinase inhibitors. The synthesized anthranilamide-
piperazine compounds were subsequently tested against a panel of kinases including EGFR, Abl, Akt and Aurora B.
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1. Introduction
Anthranilic acids and their derivatives represent a structural
motif that has seen much application in medicinal chemistry. In
the field of oncology, a wide variety of substituted anthranilic
acids have been tested and found to have cytotoxic activity
against cancerous cells.1–5 In particular, it has been noted that this
scaffold is a privileged structure when dealing with kinase inhi-
bition.6,7 Examples include PD184352 1 (aka CI-1040) from
Parke-Davis – a MEK1 and MEK2 inhibitor, tranilast 28 and two
anthranilic acid amides, AAL993 39 and 4, prepared during a
cooperation between Novartis Pharma and Schering AG (Fig. 1).
The last three compounds were all found to inhibit vascular
endothelial growth factor (VEGF) receptor tyrosine kinase, an
important therapeutic target in the field of oncology.10
In a 2004 set of papers, anthranilic acid 5 was identified as a
possible scaffold for the inhibition of the tyrosine kinases Src and
epidermal growth factor receptor (EGFR), resulting in the devel-
opment of a potent set of benzamides and benzamidines (see for
example structures 6 in Fig. 2).11,12 EGFR is a transmembrane
protein classified as a ‘receptor tyrosine kinase’. This protein is
typically activated by the extracelluler binding of a number of
ligands, including epidermal growth factor, and has been impli-
cated in a number of important cellular processes. Importantly,
its abnormal functioning has also been implicated in numerous
human malignancies.13 The same authors extended the study of
this class of compounds to demonstrate that vascular endothe-
lial growth factor receptors (VEGFRs) were also selectively
inhibited by further inhibitors based on the same anthranilic acid
scaffold.14 Importantly, the authors of this work proposed
that molecules like 6a and 6b most likely possessed a ‘slightly
different’ binding conformation when compared to erlotinib
(Tarceva™) 7, although this was not confirmed by an X-ray
study.12 Structures 6a and 6b (Fig. 2) have been drawn to show
how the presence of an intramolecular hydrogen bond
preorganizes 6 to mimic the quinazoline-portion of known
EGFR inhibitors such as PD153035 8 and erlotinib (Tarceva™) 7,
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Figure 1 Examples of anthranilic acid-based kinase inhibitors.
* Authors for correspondence. E-mail: daniel.rauh@tu-dortmund.de / wvo@sun.ac.za
Figure 2 Design of anthranilic acid-based EGFR and VEGFR kinase
inhibitors based on the ‘internal hydrogen bond’ concept.11,12,14
although it should be realized that the aniline NH2 is unlikely to
act as an intermolecular hydrogen bond acceptor as is often
proposed for the comparative quinazoline kinase inhibitors. It
should be noted that other researchers have also designed potent
kinase inhibitors on this particular basis,15,16 and that this topic
has become an important concept in medicinal chemistry.17
In recent years, the piperazine moiety has seen increasing use
as a structural component of compounds with relevance in
oncology. As an example, and of particular relevance to this
paper, Kamal, Pal-Bhadra and co-workers have recently found
that the use of anthranilamide-piperazine conjugates, such as 9
and 10, have demonstrated interesting activity in terms of
apoptosis induction in cancer cells (Fig. 3).18,19 These same
researchers patented a series of simpler anthranilic acid deriva-
tives with the generic structure 11, as ‘potential anticancer
agents’.20
Over the past years, our respective research groups have been
interested in the design, synthesis and evaluation of small mole-
cules for the selective inhibition of topical kinases,21,22 as well as
the associated biochemical evaluations.23–25 The literature concern-
ing the use of intramolecular hydrogen bonds, as well as the
innovation of using the piperazine fragment as part of the scaf-
fold,26,27 prompted us to combine these two structural features,
resulting in the synthesis of two compound libraries. In the
present work, twelve compounds based on the anthranilic acid
skeleton and incorporating a piperazine within their structure
were synthesized following a three-step protocol, to afford
potential kinase-inhibiting anilines which were biochemically
evaluated. Secondly, a focused library based on the piperazin-
1-yl{2-[(pyridin-4-ylmethyl)amino]phenyl}methanone scaffold
was also generated.
2. Synthesis
For the first set of potential inhibitors, 4,5-dimethoxy-2-nitro-
benzoic acid 12 was converted into the corresponding acid
chloride derivative, after which treatment with a number of sub-
stituted anilines and piperazines afforded the nitroamides
13a–l in good to excellent yields over two steps (see Scheme 1
and Table 1 for details). Subsequent reduction of the nitro func-
tional group led to the desired anthranilic acid derivatives 14a–l.
These compounds were all thoroughly characterized by spectro-
scopic techniques which included 1H and 13C NMR, as well as
high resolution mass spectroscopy (HRMS).
At this point, it should also be stressed that compounds 14a and
14c were synthesized as potential reference compounds, as they
were studied in the key Nakamura study mentioned earlier.12 It
should also be mentioned here that the palladium-mediated
reduction of substrates 13a and 13c did not result in the expected
anilines 14a and 14c, but gave compounds 14b and 14d instead,
in which the bromine and chlorine atoms had been reductively
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Figure 3 Example of generalized anthranilamide-piperazine conjugates
with anti-cancer properties, as produced by Kamal et al.18–20
Scheme 1
Synthesis of ‘Library 1’. For yields see Table 1.
removed respectively. Application of an alternative reduction
method making use of iron in an acidic media, did however afford
the desired compounds 14a and 14c, albeit in less than satisfac-
tory yields.
Furthermore, a second set of anthranilic acid analogues, this
time containing pyridyl appendages, inspired by compounds 3
and 4, was also synthesized. These compounds were produced
by an initial reductive amination between the anthranilic ester
15 and 4-pyridine carboxaldehyde to afford the alkylated anilino
scaffolds 16 and 17, respectively (Scheme 2 and Table 2). Further-
more, conversion of the ester functional groups into the corre-
sponding amides, facilitated by the Lewis acid trimethyl
aluminium, then afforded the desired anthranilic acid deriva-
tives 18 and 19. These compounds thus featured a pyridine
moiety and were decorated with a range of substituted
piperazines, as shown in Scheme 2 and Table 2.
3. Biochemical Testing
As an initial screening, 12 compounds from ‘Library 1’ (14a–l)
were evaluated for their ability to inhibit the kinase EGFR, which
is commonly involved in carcinogenicity.28 Mutations in EGFR
account for 10–17 % of all non-small cell lung cancers (NSCLCs),
with L858R and short in-frame deletions of exon 19 representing
the most common activating mutations.29 In contrast to other
EGFR mutations involved in cancer, L858R does not cause resis-
tance to TKI-based therapy, but instead improves the response
to first line tyrosine kinase inhibitors such as gefitinib. Second-
ary mutations providing resistance to small molecule therapy
often appear later, as in the case of T790M.30 EGFR is a prime
target in cancer therapy, which is emphasized by the large
number of small molecules that have been developed to target
this receptor tyrosine kinase.31 Furthermore, it is closely related
to VEGFR on which the anthranilic scaffold originally was
tested. For these reasons, EGFR wt as well as its L858R and
T790M/L858R mutated species were used for testing in a
biochemical assay setup.22 The results displayed in Table 3 were
unfortunately disappointing, with only compounds 14a
(~10 µM) and 14c (~30 µM), from the Nakamura study,12 having
any interesting activity on wt and L858R mutated EGFR. The
synthesized novel compounds 14f and 14h also displayed slight
inhibitory activity >200 µM) in this assay. EGFR harboring both
activating (L858R) and gatekeeper (T790M) mutation was not
affected at all, up to compound concentrations of 200 µM.
In a further screen, it was decided to test the inhibition of the
compounds from both libraries/sets against the Abl T315I kinase
at a concentration of 10 µM. This particular kinase has been of
interest due to the lack of inhibitors available to target this
specific resistance mutation in chronic myelogenous leukemia
(CML). Ponatinib (Iclusig), which was recently approved by the
FDA, represents the only therapeutic to effectively target Abl
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Scheme 2
Synthesis of ‘Library 2’. For yields see Table 2.
Table 2 Yields for amidation reactions in Scheme 2.
Yields of benzamide formation/%
Scaffold a b c d e f
18 61 51 83 22 83 45
19 54 45 30 34 nd nd
nd = not done.
Table 1 Yields for reactions in Scheme 1.
Yield of reaction Yield of reaction
12 ® 13 13 ® 14
/%, over two steps /%
13 14
a 73 23 a,b
b – 100 c
c 56 35 b
d – 86d
e 58 43
f 68 43
g 94 40
h 100 69
i 96 100
j 76 93
k 68 75
l 71 96
m 55 – e
a Based on recovered starting material; b reduction by Fe/HCl in EtOH; c Synthe-
sized from 13a; d synthesized from 13c; e no reduced product obtained after
work-up.
T315I, but comes along with severe side effects, indicating a
rather complex pharmacology.32 The results from this assay were
not encouraging, with none of the compounds demonstrating
inhibition at this concentration, although the reference com-
pound, staurosporine, displayed the expected inhibitory effect
(See supplementary information, Fig. S1).
It was then decided to send two representative compounds
from the first set, namely compounds 14a and 14h, which had
shown some activity in the EGFR screen, for testing against the
Dundee kinase library, which comprises 95 different kinases
(see supplementary information, Figs S2 and S3).33 Of interest
was that 14a showed good inhibition of AKT2 (aka PKBb) (17 %
remaining activity at 10 µM concentration), as well as moderate
inhibition of HER4 and Aurora B (43% resp. 51% remaining
activity at 10 µM). Compound 14h also inhibited AKT2 (PKBb)
with moderate effect (64 %), as well as Aurora B (61 %) and
CAMK1 (60 %). The two libraries, comprising compounds 14a–l,
18a–f and 19a–d, were then evaluated for their ability to
inhibit Akt2 (PKBb) and its close isoform Akt1 (PKBa), with the
enzymes at full length (Akt1 and Akt2) or kinase domain only
(Akt1). Unfortunately, the results showed that the compounds
did not effectively inhibit the kinases either (see supplementary
information, S4).34 Finally, as the Dundee screen had also shown
14a and 14h to inhibit Aurora B, both compounds were sent for
testing against this particular kinase to Reaction Biology Corp.35
Compounds 14a and 14h were subsequently tested in 10-dose
IC50 mode with threefold serial dilution starting at 300 µM and in
the presence of 20 µM ATP. Unfortunately, both compounds
showed little activity (IC50 >300 µM)
36 in comparison to the
positive control staurosporine, which had an IC50 of 5 nM.
4. Conclusion
The present paper presents the synthesis of anthranilic acid-
derived molecules inspired by known kinase inhibitors such as
Tranilast and AAL993. A particularity of our set of molecules is
the piperazine fragment included in their core structure. The
synthesized anthranilamide-piperazine conjugates were then
tested against the following kinases: EGFR (wt, L858R and
T790M/L858R), Abl_T315I, Akt1 (PKBa), Akt2 (PKBb) and
Aurora B. These tests indicated that unfortunately none of the
compounds inhibited the kinases enough to warrant further
extension of these libraries.
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Experimental
General Experimental Information
1H NMR and 13C NMR spectra were recorded on Bruker 300,
Bruker DRX 400, Varian Inova 400 or Varian Inova 300 spectrom-
eters at the frequency indicated. Infra-red spectra were recorded
on Bruker IFS 25, Bruker Vector 22 or Thermo Nicolet Nexus 470
fourier transform spectrometers. Mass spectra were recorded
on a Kratos MS 9/50, VG 70E MS or VG 70 SEQ mass spectrometer
or alternatively a Waters API Q-TOF Ultima, GCT Premier or
SYNAPT G2 mass spectrometer. Prior to being evaluated for
HRMS all compounds were checked by LCMS for a purity of
>80 %. Macherey-Nagel kieselgel 60 (particle size 0.063–0.200 mm)
was used for conventional silica gel chromatography. All solvents
used for reactions and chromatography were distilled prior to
use. Reactions were performed under a blanket of inert gas (Ar
or N2) unless specified. Melting points are uncorrected.
General Experimental Procedure for the Synthesis of
N-phenylbenzamides 13a–m from Benzoic Acid 12
4,5-Dimethoxy-2-nitrobenzoic acid 12 (0.23 g, 1.0 mmol) was
dissolved in SOCl2 (1 mL) and the reaction was stirred at 75 °C for
3 h under an Ar atmosphere. The excess SOCl2 was then removed
under reduced pressure using a liquid nitrogen trap. CH2Cl2
(5 mL) was then added to the remaining residue, followed by the
addition of the substituted aniline (1.1 mmol, 1.1 mol equiv.) and
NEt3 (0.41 mL, 3.0 mmol) and the reaction was stirred at RT,
under Ar for 18 h. The organic solvent was removed under
reduced pressure and EtOAc (20 mL) was added. The organic
fraction was washed sequentially with HCl (10 mL, 1 M), H2O
(20 mL), aq. NaOH (10 mL, 2 M) and H2O (20 mL). The organic
fraction was then dried (MgSO4) and removed in vacuo. The
desired amide was then obtained after column chromatography
on flash silica (eluent: 40–50 % EtOAc/cyclohexane or as
indicated). If required, recrystallization was also performed to
provide purified compounds.
N-(3-Bromophenyl)-4,5-dimethoxy-2-nitrobenzamide 13a
Obtained as a yellow-coloured semi-solid after purification by
way of column chromatography (Eluent: 50 % EtOAc/cyclohex-
ane); yield 73 %; 1H NMR (400 MHz, DMSO-d6) d 10.69 (s, 1H),
8.03 (d, J = 1.7 Hz, 1H), 7.73 (s, 1H), 7.62–7.56 (m, 1H), 7.35–7.31
(m, 3H), 3.94 (s, 3H), 3.93 (s, 3H); 13C NMR (101 MHz, DMSO-d6)
d 164.4, 153.1, 149.1, 140.6, 138.6, 130.8, 126.9, 126.3, 121.8, 121.5,
118.3, 111.1, 107.3, 56.7, 56.4; HRMS Calculated 381.0081 (M+ +
H) for C15H14BrN2O5, found 381.0085.
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Table 3 In vitro determined IC50s on different EGFR species.
IC50 /µM
Compound EGFR wt EGFR L858R EGFR T790M/L858R
14a 11.4 ± 2.9 6.1 ± 1.1 ni
14b ni ni ni
14c 31.4 ± 8.1 29.9 ± 13.7 ni
14d ni ni ni
14e ni ni ni
14f >200 >200 ni
14g ni ni ni
14h ³200 >200 ni
14i ni ni ni
14j ni ni ni
14k ni ni ni
14l ni ni ni
ni: no inhibitory effect at 200 µM compound concentration.
N-(3-Chloro-4-fluorophenyl)-4,5-dimethoxy-2-nitrobenz-
amide 13c
Obtained as a yellow-coloured solid after purification by
way of column chromatography (Eluent: 40 % EtOAc/cyclohex-
ane), followed by recrystallization from EtOAc; yield 56 %; mp
218–220 °C; 1H NMR (400 MHz, DMSO-d6) d 10.72 (s, 1H), 7.97
(dd, J = 6.8, 2.6 Hz, 1H), 7.72 (s, 1H), 7.56–7.53 (m, 1H), 7.44–7.40
(m, 1H), 7.31 (s, 1H), 3.94 (s, 3H), 3.92 (s, 3H); 13C NMR (101 MHz,
DMSO-d6) d 164.3, 153.4 (d, J = 243.6 Hz), 153.1, 149.1, 138.6
(d, J = 3.0 Hz), 136.2, 126.8, 120.9, 119.9 (d, J = 6.8 Hz), 119.2 (d, J =
18.1 Hz), 117.2 (d, J = 21.5 Hz), 111.1, 107.3, 56.7, 56.4; HRMS Cal-
culated 357.0462 (M+ + H) for C15H13
37ClFN2O5, found 357.0463.
N-(3,4-Dimethoxyphenyl)-4,5-dimethoxy-2-nitrobenzamide 13e
Obtained as a yellow-coloured solid after purification by
way of column chromatography (Eluent: 70 % EtOAc/cyclohex-
ane), followed by recrystallization from EtOAc; yield 58 %; mp
185–188 °C; 1H NMR (400 MHz, CDCl3) d 7.92 (s, 1H), 7.48 (s, 1H),
7.23 (d, J = 2.4 Hz, 1H), 6.97–6.90 (m, 2H), 6.76 (d, J = 8.7 Hz, 1H),
3.94 (s, 3H), 3.92 (s, 3H), 3.84 (s, 3H), 3.80 (s, 3H); 13C NMR
(101 MHz, CD3OD) d 166.2, 153.9, 149.2, 148.9, 146.4, 138.9, 132.1,
127.8, 113.2, 111.8, 110.6, 107.4, 105.7, 56.8, 56.6, 56.2, 55.9; HRMS
Calculated 363.1187 (M+ + H) for C17H19N2O7, found 363.1188.
N-(3-Ethynylphenyl)-4,5-dimethoxy-2-nitrobenzamide 13f
Obtained as a yellow-coloured solid after purification by
way of column chromatography (Eluent: 10 % MeOH/EtOAc);
yield 68 %; mp 179–181 °C; 1H NMR (400 MHz, DMSO-d6) d 10.60
(s, 1H), 7.85 (s, 1H), 7.71 (s, 1H), 7.63 (d, J = 9.4 Hz, 1H), 7.39–7.35
(m, 1H), 7.30 (s, 1H), 7.22 (d, J = 7.6 Hz, 1H), 4.20 (s, 1H), 3.94 (s,
3H), 3.92 (s, 3H); 13C NMR (101 MHz, DMSO-d6) d 164.3, 153.1,
149.0, 139.2, 138.6, 129.3, 127.1, 126.9, 122.4, 122.1, 120.1, 111.1,
107.3, 83.3, 80.7, 56.7, 56.4; HRMS Calculated 327.0981 (M+ + H)
for C17H15N2O5, found 327.0980.
2-[4-(4,5-Dimethoxy-2-nitrobenzoyl)-1-piperazinyl]pyrimi-
dine 13 g
Obtained as white crystals (recrystalized from EtOAc);
yield 94 %; mp 232–234 °C; 1H NMR (400 MHz, CDCl3) d 8.30 (d,
J = 4.8 Hz, 2H), 7.72 (s, 1H), 6.77 (s, 1H), 6.55–6.51 (m, 1H), 3.98 (s,
3H), 3.97 (s, 3H), 3.99–3.95 (m, 6H), 3.25 (t, J = 5.3, 2H); 13C NMR
(101 MHz, CDCl3) d 166.8, 161.5, 157.7, 154.3, 149.2, 137.9, 126.9,
110.5, 109.07, 107.3, 56.7, 56.5, 46.5, 43.5, 43.1, 41.8; HRMS Calcu-
lated 374.1460 (M+ + H) for C17H20N5O5, found 374.1459.
1-(3,4-Dichlorophenyl)-4-(4,5-dimethoxy-2-nitrobenzoyl)
piperazine 13h
Obtained as a pale yellow foam (deemed pure enough after
work-up); yield quantitative; 1H NMR (400 MHz, CDCl3) d 7.69
(s, 1H), 7.52 (d, J = 8.9 Hz, 1H), 6.91 (d, J = 2.9 Hz, 1H), 6.74 (s, 1H),
6.70 (dd, J = 2.9, 8.9 Hz, 1H), 3.95 (s, 3H), 3.94 (s, 3H), 3.30–3.01 (m,
8H); 13C NMR (101 MHz, CDCl3) d 166.5, 154.3, 150.2, 149.2, 137.8,
132.9, 130.5, 126.5, 123.2, 118.0, 116.1, 109.0, 107.2, 60.4, 56.5, 48.8,
48.6, 46.2, 41.5; HRMS Calculated 440.0773 (M+ + H) for
C19H20Cl2N3O5, found 440.0775.
1-(4,5-Dimethoxy-2-nitrobenzoyl)-4-methylpiperazine 13i
Obtained as a pale yellow foam (deemed pure enough
after work-up); yield 96 %; 1H NMR (400 MHz, CDCl3) d 7.69 (s,
1H), 6.73 (s, 1H), 3.95 (br s, 6H), 3.19 (t, J = 5.1 Hz, 2H), 2.56–2.48
(m, 6H), 2.30 (s, 3H); 13C NMR (101 MHz, CDCl3) d 166.3, 154.2,
149.1, 137.8, 127.0, 109.1, 107.2, 56.7, 56.5, 54.6, 54.1, 46.6, 46.0,
41.7; HRMS Calculated 310.1398 (M+ + H) for C14H20N3O5, found
310.1398.
1-Benzoyl-4-(4,5-dimethoxy-2-nitrobenzoyl)piperazine 13j
Obtained as pale yellow crystals (recrystalized from EtOAc);
yield 76 %; mp 185–187 °C; 1H NMR (400 MHz, CDCl3) d 7.69 (br s,
1H), 7.40 (br s, 5H), 6.74 (s, 1H), 4.10–4.00 (br M, 1H), 4.00–3.95
(br M, 1H), 3.96 (br s, 6H), 3.75–3.50 (br M, 4H), 3.30–3.15 (br M,
2H); 13C NMR (101 MHz, CDCl3) d 170.6, 166.7, 154.4, 149.3, 137.8,
135.0, 130.1, 128.6, 127.0, 126.4, 108.9, 107.3, 56.7, 56.5, 46.7 (br),
42.0 (br); HRMS Calculated 400.1496 (M+ + H) for C20H22N3O6,
found 400.1503.
1-(4,5-Dimethoxy-2-nitrobenzoyl)-4-(2-phenylethyl)
piperazine 13k
Obtained as a pale yellow semi-solid (purified by silica gel
column chromatography: 10 % MeOH-EtOAc); yield 68 %;
1H NMR (400 MHz, CDCl3) d 7.69 (s, 1H), 7.33–7.09 (m, 5H), 6.74
(s, 1H), 3.95 (br s, 6H), 3.95–3.90 (br M, 1H), 3.79–3.71 (br M, 1H),
3.21 (t, J = 5.1 Hz, 2H), 2.81–2.74 (br M, 2H), 2.71–2.54 (br M, 4H),
2.45–2.33 (br M, 2H); 13C NMR (101 MHz, CDCl3) d 166.3, 154.2,
149.0, 139.9, 137.8, 128.6, 128.3, 127.0, 126.1, 109.1, 107.2, 60.0, 56.6,
56.5, 52.7, 52.1, 46.6, 41.8, 33.5; HRMS Calculated 400.1859 (M+ +
H) for C21H26N3O5, found 400.1867.
2-[4-(4,5-Dimethoxy-2-nitrobenzoyl)-1-piperazinyl]
ethanol 13l
Obtained as a pale yellow oil; yield 71 %, (deemed pure
enough after work-up); 1H NMR (400 MHz, CD3OD) d 7.78 (s,
1H), 6.97 (s, 1H), 3.96 (s, 3H), 3.95 (s, 3H), 3.91–3.84 (br M, 1H),
3.78–3.72 (br M, 1H), 3.69 (t, J = 5.1 Hz, 2H), 3.32–3.27 (m, 2H),
2.67 (t, J = 5.1 Hz, 2H), 2.58 (t, J = 5.8 Hz, 2H), 2.52–2.45 (m, 2H);
13C NMR (101 MHz, CD3OD) d 169.0, 156.1, 151.0, 139.3, 127.5,
110.6, 108.5, 61.2, 59.8, 57.4, 57.0, 54.1, 53.6, 47.9, 42.8; HRMS
Calculated 340.1504 (M+ + H) for C15H22N3O6, found 340.1503.
N-{2-[4-(4,5-Dimethoxy-2-nitrobenzoyl)-1-piperazinyl]ethyl}-
N,N-dimethylamine 13m
Obtained as a yellow oil; yield 55 %, (deemed pure enough
after work-up); 1H NMR (400 MHz, CDCl3) d 7.69 (s, 1H), 6.73 (s,
1H), 3.77 (s, 6H), 3.93–3.87 (br M, 1H), 3.76–3.70 (br M, 1H), 3.19 (t,
J = 5.1 Hz, 2H), 2.67–2.60 (br M, 1H), 2.56–2.52 (br M, 1H),
2.51–2.47 (br M, 2H), 2.43–2.36 (br M, 4H), 2.22 (s, 6H); 13C NMR
(101 MHz, CDCl3) d 166.3, 154.2, 149.0, 137.8, 127.0, 109.1, 107.2,
56.8, 56.7, 56.5, 56.4, 53.2, 52.6, 46.6, 45.8, 41.8; HRMS Calculated
367.1978 (M+ + H) for C17H27N4O5, found 367.1976.
General Procedure 1: Synthesis of 2-Amino-N-phenylbenz-
amides 14 by way of the Pd/C Reduction of 2-Nitro-N-
phenylbenzamides 13
The 2-nitro-N-phenylbenzamides 13 (~0.5 mmol) were dissolved
in EtOH (5 mL), after which 5 % Pd/C (10 % by mass) was added
carefully. This was followed by the addition of ammonium
formate (5. Mol equiv.), after which the reaction mixture was
heated at reflux, with stirring, for 90 min. After cooling to RT, the
mixture was filtered through a Celite plug and the filter cake
washed with EtOH (3 × 5 mL). The solvent was removed to
afford the anilines 14, which in general were judged by 1H NMR
spectroscopy to be pure enough for biochemical evaluation; if
not, flash silica gel column chromatography was employed. See
individual descriptions for specific experimental details below.
2-Amino-N-(3-bromophenyl)-4,5-dimethoxybenzamide 14a
For this particular compound, the general reduction described
above resulted in the formation of 14b in which the aromatic
bromide had also been removed. An alternative reduction
method, involved the treatment of 13a (0.060 g, 0.16 mmol)
in EtOH (2 mL) with elemental iron (0.044 g, 0.80 mmol)
with HCl (12 M, 0.7 mL) for 5.5 h at reflux. H2O (10 mL) was then
added, after which the mixture was basified by the addition of
NaOH solution (2 M). Extraction with EtOAC (3 × 5 mL), wash-
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ing with brine (10 mL), drying with Na2SO4 and removal of
solvent under reduced pressure, afforded a mixture of the
desired product and starting material. Silica gel column chroma-
tography (50 % EtOAc/hexanes) then resulted in 14a as a yellow
semi-solid (0.010 g, 17 %), in addition to starting material 13a
(20 %). The NMR spectra of 14a compared well with that
published in the literature.12 1H NMR (400 MHz, CD3OD)
d 7.98–7.94 (m, 1H), 7.63–7.57 (m, 1H), 7.28 (d, J = 1.2 Hz, 1H),
7.27–7.26 (m, 2H), 6.46 (s, 1H), 3.87 (s, 3H), 3.85 (s, 3H).
2-Amino-4,5-dimethoxy-N-phenylbenzamide 14b
For this particular compound, use of the general procedure
described above resulted in removal of the bromine atom
and 14b was thus obtained as a beige solid (quantitative yield).
The NMR spectra of 14b compared well with that published in
the literature.37 1H NMR (400 MHz, CD3OD) d 7.66 (dd, J = 7.7,
0.9 Hz, 2H), 7.44–7.41 (m, 2H), 7.33 (br s, 1H), 7.21–7.19 (m, 1H),
6.50 (br s, 1H), 3.94 (s, 3H), 3.93 (s, 3H).
2-Amino-N-(3-chloro-4-fluorophenyl)-4,5-dimethoxy-
benzamide 14c
For this particular compound, the general reduction described
above resulted in the formation of 14c in which the aromatic
chloride had also been removed (see spectroscopic description
below). An alternative reduction method, involved the treat-
ment of 13c (0.070 g, 0.20 mmol) in EtOH (2 mL) with elemental
iron (0.10 g, 2.0 mmol added in two portions at start of reaction
and after 5.5 h) with HCl (12 M, 0.8 mL) for 28 h at reflux. H2O
(10 mL) was then added, after which the mixture was made basic
by the addition of NaOH solution (2 M). Extraction with EtOAC
(3 × 5 mL), washing with brine (10 mL), drying with Na2SO4 and
removal of solvent under reduced pressure, afforded a mixture of
the desired product and starting material. Silica gel column
chromatography (50 % EtOAc/hexanes) then resulted in 14c as
a light yellow-coloured semi-solid (0.022 g, 35 %). The NMR
spectra of 14c compared well with that published in the litera-
ture.12 1H NMR (400 MHz, CD3OD) d 7.93–7.89 (m, 1H), 7.60–7.57
(m, 1H), 7.30 (s, 1H), 7.27–7.21 (m, 1H), 6.49 (s, 1H), 3.94 (s, 3H),
3.92 (s, 3H).
2-Amino-N-(4-fluorophenyl)-4,5-dimethoxybenzamide 14d
Obtained as pale yellow oil (purified by silica gel column
chromatography: 50 % EtOAc-hexane), yield 86 %; 1H NMR
(400 MHz, CD3OD) d 7.60–7.53 (m, 2H), 7.22 (s, 1H), 7.09–7.01 (m,
2H), 6.40 (s, 1H), 4.82 (s, 3H), 3.82 (s, 3H), 3.86 (s, 3H); 13C NMR
(101 MHz, CD3OD) d 168.8, 160.4 (d), 154.0, 145.9, 141.1, 134.8 (d),
123.8 (d), 115.1 (d), 112.6 (d), 107.9, 101.3, 57.3, 55.6; HRMS Calcu-
lated 291.1140 (M+ + H) for C15H16N2O3F, found 291.1140.
2-Amino-N-(3,4-dimethoxyphenyl)-4,5-dimethoxybenzamide
14e
Obtained as an off-white foam (purified by silica gel column
chromatography: EtOAc), yield 43 %; 1H NMR (400 MHz,
CD3OD) d 7.28 (d, J = 2.4 Hz, 1H), 7.22 (s, 1H), 7.09 (dd, J = 8.6,
2.4 Hz, 1H), 6.89 (d, J = 8.7 Hz, 1H), 6.40 (s, 1H), 4.82 (s, 3H), 3.80
(s, 3H), 3.81 (s, 3H), 3.79 (s, 3H), 3.78 (s, 3H); 13C NMR (101 MHz,
CD3OD) d 169.9, 155.1, 150.3, 147.4, 147.3, 141.8, 133.6, 115.3,
114.0, 113.2, 108.5, 108.2, 101.8, 57.7, 56.7, 56.4, 56.1; HRMS Calcu-
lated 333.1445 (M+ + H) for C17H21N2O5, found 333.1446.
2-Amino-N-(3-ethynylphenyl)-4,5-dimethoxybenzamide 14f
Obtained as an off-white semi-solid (purified by silica gel
column chromatography: 50 % EtOAc-hexane), yield 43 %,
1H NMR (400 MHz, CD3OD, alkyne proton not observed in spec-
trum) d 7.90–7.89 (m, 1H), 7.74–7.73 (m, 1H), 7.46–7.39 (m, 1H),
7.37–7.32 (m, 2H), 6.53 (s, 1H), 3.98 (s, 3H), 3.97 (s, 3H); 13C NMR
(101 MHz, CD3OD) d 169.5, 154.7, 146.9, 141.4, 139.7, 129.4, 128.3,
125.6, 123.6, 122.7, 113.3, 108.0, 101.6, 84.0, 78.1, 57.5, 56.1; HRMS
Calculated 297.1234 (M+ + H) for C17H17N2O3, found 297.1235.
4,5-Dimethoxy-2-{[4-(2-pyrimidinyl)-1-piperazinyl]carbonyl}
phenylamine 14g
Obtained as a pale yellow semi-solid, (purified by silica gel
column chromatography: 5 % MeOH/EtOAc); yield 40 %;
1H NMR (400 MHz, CDCl3) d 8.31 (d, J = 4.7 Hz, 2H), 6.66 (s, 1H),
6.52 (t, J = 4.7 Hz, 1H), 6.26 (s, 1H), 4.27 (br s, 2H), 3.88–3.84 (m,
4H), 3.84 (s, 3H), 3.76 (s, 3H), 3.71–3.62 (m, 4H); 13C NMR
(100 MHz, CDCl3) d 170.4, 161.5, 157.7, 151.7, 141.3, 141.1, 112.2,
110.4, 110.0, 101.0, 56.7, 55.8, 45.1 (br), 43.9; HRMS Calculated
344.1717 (M+ + H) for C17H22N5O3, found 344.1718.
2-{[4-(3,4-Dichlorophenyl)-1-piperazinyl]carbonyl}-4,5-
dimethoxyphenylamine 14h
Obtained as a pale beige-coloured oil, (purified by silica gel
column chromatography: EtOAc), yield 69 %; 1H NMR
(400 MHz, CD3OD) d 7.29 (d, J = 8.9 Hz, 1H), 7.06 (d, J = 2.9 Hz,
1H), 6.86 (dd, J = 9.0, 2.9 Hz, 1H), 6.72 (s, 1H), 6.45 (s, 1H), 3.79 (s,
3H), 3.84 (s, 3H), 3.84–3.80 (m, 4H), 3.24–3.14 (m, 4H); 13C NMR
(100 MHz, CD3OD, one aliphatic carbon not observed in spec-
trum) d 172.0, 153.5, 152.1, 142.7, 142.4, 133.6, 131.6, 123.2, 118.6,
117.1, 114.3, 111.5, 102.2, 57.6, 56.2, 49.4 (br); HRMS Calculated
410.1033 (M+ + H) for C19H22N3O3Cl2, found 410.1031.
4,5-Dimethoxy-2-[(4-methyl-1-piperazinyl)carbonyl]phenyl-
amine 14i
Obtained as a pale yellow oil which slowly solidified to a
semi-solid; yield quantitative; 1H NMR (400 MHz, CD3OD) d 6.69
(s, 1H), 6.45 (s, 1H), 3.80 (s, 3H), 3.73 (s, 3H), 3.64–3.59 (m, 4H),
2.53–2.40 (m, 4H), 2.31 (s, 3H); 13C NMR (100 MHz, CD3OD, one
aliphatic carbon not observed in spectrum) d 180.8, 162.3, 151.4,
151.2, 122.9, 120.4, 110.9, 66.4, 65.0, 64.7, 54.8; HRMS Calculated
280.1656 (M+ + H) for C14H22N3O3, found 280.1656.
2-[(4-Benzoyl-1-piperazinyl)carbonyl]-4,5-dimethoxyphenyl-
amine 14j
Obtained as a light yellow oil, (purified by silica gel column
chromatography: 5 % MeOH/EtOAc); yield 93 %; 1H NMR
(400 MHz, CDCl3) d 7.38 (s, 5H), 6.60 (s, 1H), 6.23 (s, 1H), 4.48 (s,
2H), 3.79 (s, 3H), 3.74 (s, 3H), 3.77–3.44 (m, 8H); 13C NMR
(100 MHz, CDCl3) d 170.6, 151.9, 141.3, 141.1, 135.1, 130.0, 128.5,
127.0, 112.1, 109.4, 101.0, 56.7, 55.7, 47.4 (br), 45.2 (br); HRMS
Calculated 370.1761 (M+ + H) for C20H24N3O4, found 370.1762.
4,5–Dimethoxy-2-{[4-(2-phenylethyl)-1-piperazinyl]carbonyl}
phenylamine 14k
Obtained as a yellow oil (purified by silica gel column chroma-
tography: 10 % MeOH/EtOAc); yield 75 %; 1H NMR (400 MHz,
CD3OD) d 7.34–7.05 (m, 5H), 6.69 (s, 1H), 6.45 (s, 1H), 3.78 (s, 3H),
3.72 (s, 3H), 3.65–3.61 (m, 4H), 2.84–2.77 (m, 2H), 2.68–2.61 (m,
2H), 2.60–2.58 (m, 4H); 13C NMR (100 MHz, CD3OD, one aliphatic
carbon not observed in spectrum) d 171.8, 153.5, 142.6, 142.4,
141.0, 129.7, 129.5, 127.2, 114.2, 111.6, 102.2, 61.1, 57.6, 56.2, 54.1,
45.7 (br), 33.9; HRMS Calculated 370.2125 (M+ + H) for
C21H28N3O3, found 370.2127.
2-[4-(2-Amino-4,5-dimethoxybenzoyl)-1-piperazinyl]ethanol 14l
Pale yellow oil; yield 96 %; 1H NMR (400 MHz, CD3OD) d 6.69
(s, 1H), 6.44 (s, 1H), 3.78 (s, 3H), 3.71 (s, 3H), 3.76–3.63 (m, 6H),
2.74–2.68 (m, 6H); 13C NMR (100 MHz, CD3OD, one aliphatic
carbon not observed) d 171.8, 153.5, 142.7, 142.3, 114.2, 111.3,
111.1, 102.1, 60.8, 59.1, 57.6, 56.2, 54.2, 45.2 (br), 45.0 (br); HRMS
Calculated 310.1761 (M+ + H) for C15H24N3O4, found 310.1763.
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General Synthesis of [(Pyridinylmethyl)amino]benzoates 16
and 17
The methyl 2-aminobenzoates 15a or 15b (5–7 mmol) were
dissolved in MeOH (96 %, ~50 mL), to which 4-pyridine
carboxaldehyde (1.3 mol equiv.) was added. After the addition of
AcOH (0.6 mL) the reaction mixture was stirred at RT for
3–5 days under a N2 atmosphere. NaCNBH3 (1.3 mol equiv.) was
subsequently added in small increments over a period of 30 min
and the reaction mixture left to stir for a further 3–4 h. The solvent
was then removed under reduced pressure to afford a gummy
residue. EtOAc (8 mL) was used to dissolve the residue after
which the organic phase was washed sequentially with aqueous
NaHCO3 (sat., 100 mL) and brine (100 mL). The organic layer was
then dried (Na2SO4), filtered and reduced under vacuum. The
resulting residue was purified with silica gel column chromatog-
raphy (70 % EtOAc-hexane) to afford semi-solids from which the
pure products 16 or 17 were obtained by recrystallization (1:1
EtOAc/hexane) – see below for individual descriptions of products
obtained.
Methyl 4,5-dimethoxy-2-[(4-pyridinylmethyl)amino]
benzoate 16
Obtained as a white solid; yield 65 %; mp 142–144 °C; 1H NMR
(300 MHz, CDCl3): d 8.54 (d, J = 5.4 Hz, 2H), 8.24 (br t, J = 4.9 Hz,
1H), 7.40 (s, 1H), 7.28 (d, J = 5.4 Hz, 2H), 5.94 (s, 1H), 4.47 (d,
J = 5.7 Hz, 2H), 3.87 (s, 3H), 3.82 (s, 3H), 3.70 (s, 3H); 13C NMR
(75 MHz, CDCl3) d 168.6, 155.2, 150.1, 148.5, 147.6, 139.7, 121.9,
113.8, 101.6, 94.9, 56.5, 55.6, 51.4, 46.3; HRMS Calculated 303.1339
(M+ + H) for C16H19N2O4, found 303.1333.
Methyl 2-[(pyridin-4-ylmethyl)amino]benzoate 17
For this particular compound, use of the general procedure
described above on substrate 15b, resulted in the product 17
being obtained as a white solid (65 %). The NMR spectra of 17
compared well with that published in the literature.9 1H NMR
(300 MHz, CDCl3) 8.52 (d, J = 6.0 Hz, 2H), 8.30–8.26 (m, 1H), 7.92
(dd, J = 8.0 Hz, 1.6 Hz, 1H), 7.24–7.39 (m, 3H), 6.61–6.57 (m, 1H),
6.44 (d, J = 8.5 Hz, 1H), 4.46–4.42 (m, 2H), 3.87 (s, 3H).
General Description Involving the Synthesis of Piperazin-1-
yl{2-[(pyridin-4-ylmethyl)amino]phenyl}methanones 18
and 19, from Methyl [(pyridinylmethyl)amino]benzoates 16
and 17:38
A solution of AlMe3 in toluene (1.5 mol equiv., 2 M) was added
to the methyl benzoate 16 or 17 (1.0 mmol) dissolved in toluene
(3.5 mL) in a round-bottomed flask. The appropriate piperazine
(1.4 mol equiv.) was then added, together with an additional
volume of toluene (3.5 mL). The reaction mixture was then
stirred at RT for 1 h, before being stirred under heating at 110 °C
for an additional 1 h. The solvent was then removed under
reduced pressure. EtOAc (10 mL) was then used to dissolve the
residue, after which the organic phase was washed sequentially
with aqueous NaHCO3 (sat., 50 mL) and brine (50 mL). The
organic layer was dried (Na2SO4), filtered and removed under
reduced pressure, resulting in a dark yellow oil. This residue
was purified by silica gel column chromatography (90 %
EtOAc/MeOH) to obtain the desired products 18 or 19, for which
the details are given below.
4,5-Dimethoxy-2-(1-piperazinylcarbonyl)-N-(4-pyridinyl
methyl)aniline 18a
Obtained as a pale yellow solid; yield 61 %; mp 109–111 °C;
1H NMR (300 MHz, CDCl3, one proton not observed in spec-
trum) d 8.54 (d, J = 6.0 Hz, 2H), 7.30 (d, J = 6.0 Hz, 2H), 6.71 (s,
1H), 6.06 (s, 1H), 5.85 (br t, J = 6.0 Hz, 1H), 4.37 (d, J = 6.0 Hz, 2H),
3.78 (s, 3H), 3.69 (s, 3H), 3.63 (br t, J = 5.9 Hz, 4H), 2.90 (br t,
J = 5.9 Hz, 4H); 13C NMR (75 MHz, CDCl3) d 170.4, 151.8, 149.9,
148.9, 142.6, 140.1, 122.0, 113.3, 109.8, 97.1, 57.0, 55.6, 47.0, 46.4
(2C); HRMS Calculated 357.1921 (M+ + H) for C19H25N4O3, found
357.1920.
2-[(4-Ethyl-1-piperazinyl)carbonyl]-4,5-dimethoxy-N-
(4-pyridinylmethyl)aniline 18b
Obtained as a pale yellow solid; yield 51 %; mp 55–56 °C,
1H NMR (300 MHz, CDCl3) d 8.55 (d, J = 6.0 Hz, 2H), 7.28 (d,
J = 6.0 Hz, 2H), 6.71 (s, 1H), 6.05 (s, 1H), 5.87 (br t, J = 6.1 Hz, 1H),
4.37 (d, J = 6.1 Hz, 2H), 3.78 (s, 3H), 3.72–3.68 (m, 7H), 2.50–2.43
(m, 6H), 1.09 (t, J = 6.0 Hz, 3H); 13C NMR (75 MHz, CDCl3) d 170.4,
152.0, 150.1, 148.9, 142.9, 140.1, 122.0, 113.5, 109.7, 97.2, 57.1, 55.7,
53.1, 52.3, 47.1, 45.5 (br), 12.0; HRMS Calculated 385.2234 (M+ +
H) for C21H29N4O3, found 385.2235.
4,5-Dimethoxy-N-(4-pyridinylmethyl)-2-{[4-(2-pyridinyl)-1-
piperazinyl]carbonyl}aniline 18c
Obtained as an orange oil; yield 83 %; 1H NMR (300 MHz,
CDCl3): d 8.68 (d, J = 4.5, 2H), 8.22 (br d, J = 5.2 Hz, 1H), 7.55–7.50
(m, 1H), 7.30–7.28 (d, J = 6.0 Hz, 2H), 6.78–6.76 (m, 1H), 6.71–6.67
(m, 2H), 6.07 (s, 1H), 6.03–5.99 (m, 1H), 4.44 (d, J = 7.4 Hz, 2H),
3.79–3.77 (m, 7H), 3.70 (s, 3H), 3.64–3.60 (m, 4H); 13C NMR
(75 MHz, CDCl3): d 170.8, 159.1, 152.2 , 150.1, 148.7, 148.0, 143.2,
140.1, 137.7, 122.0, 114.0, 113.5, 109.3, 107.3, 97.3, 57.0, 55.7, 47.1,
45.6, 45.2; HRMS Calculated 434.2187 (M+ + H) for C24H28N5O3,
found 434.2184.
4,5-Dimethoxy-N-(4-pyridinylmethyl)-2-{[4-(4-pyridinyl)-1-pi
perazinyl]carbonyl}aniline 18d
Obtained as a dark yellow oil; yield 22 %; 1H NMR (300 MHz,
CDCl3): d 8.54 (d, J = 4.8 Hz, 2H), 8.31 (d, J = 5.3 Hz, 2H), 7.31 (d,
J = 5.2 Hz, 2H), 6.74 (s, 1H), 6.69 (br s, 2H), 6.08 (br s, 2H), 4.39 (br
s, 2H), 3.80–3.79 (br M, 7H), 3.71 (s, 3H), 3.42 (br s, 4H); 13C NMR
(75 MHz, CDCl3): d 170.9, 154.7, 152.4, 150.1, 150.0, 148.7, 143.4,
140.1, 122.0, 113.6, 108.7, 108.6, 97.2, 57.1, 55.7, 47.0, 46.2, 44.7;
HRMS Calculated 434.2187 (M+ + H) for C24H28N5O3, found
434.2183.
4,5-Dimethoxy-N-(4-pyridinylmethyl)-2-{[4-(2-pyridinyl)-1-
piperazinyl]carbonyl}aniline 18e
Obtained as a dark yellow oil; yield 83 %; 1H NMR (300 MHz,
CDCl3): d 8.54 (d, J = 4.5 Hz, 2H), 8.34 (d, J = 4.8 Hz, 2H), 7.30 (d,
J = 6.0 Hz, 2H), 6.75 (s, 1H), 6.56–6.53 (m, 1H), 6.07 (s, 1H),
6.03–5.99 (m, 1H), 4.39 (d, J = 5.3 Hz, 2H), 3.92–3.89 (br M, 4H),
3.79 (s, 3H), 3.76–3.72 (m, 4H), 3.70 (s, 3H); 13C NMR (75 MHz,
CDCl3): d 170.8, 161.6, 157.8, 152.1, 150.0, 148.8, 143.1, 140.2, 122.0,
113.5, 110.5, 109.3, 97.2, 57.0, 56.2, 47.1, 45.3, 44.0; HRMS Calcu-
lated 435.2139 (M+ + H) for C23H27N6O3, found 435.2135.
4,5-Dimethoxy-2-{[4-(2-phenylethyl)-1-piperazinyl]
carbonyl}-N-(4-pyridinylmethyl)aniline 18f
Obtained as a yellow oil; yield 45 %; 1H NMR (400 MHz, CDCl3)
d 8.53 (d, J = 5.8 Hz, 2H), 7.28 (d, J = 4.9 Hz, 4H), 7.22–7.18 (m,
4H), 6.70 (s, 1H), 6.04 (s, 1H), 4.36 (s, 2H), 3.77 (d, J = 3.2 Hz, 4H),
3.68 (d, J = 4.0 Hz, 6H), 2.83–2.79 (m, 2H), 2.68–2.63 (m, 2H),
2.57–2.54 (m, 4H); 13C NMR (101 MHz, CDCl3) d 170.8, 152.3,
150.9, 150.4, 149.32, 143.2, 140.4, 140.2, 129.1, 128.8, 126.6, 122.4,
113.8, 109.9, 97.5, 60.6, 57.4, 56.1, 53.8, 47.5, 33.8; HRMS Calcu-
lated 461.2547 (M+ + H) for C27H33N4O3, found 461.2543.
2-(1-Piperazinylcarbonyl)-N-(4-pyridinylmethyl)aniline 19a
Obtained as a pale yellow solid; yield 54 %; mp 84–86 °C,
1H NMR (300 MHz, CDCl3) d 8.53 (d, J = 6.0 Hz, 2H), 7.26 (d, J =
6.0 Hz, 2H), 7.18–7.10 (m, 2H), 6.72–6.67 (m, 1H), 6.47 (d, J =
9.0 Hz, 1H), 5.76 (br t, J = 6.1, 1H), 4.39 (d, J = 6.1 Hz, 2H), 3.64 (br
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s, 4H), 2.91–2.87 (m, 4H); 13C NMR (75 MHz, CDCl3, one carbon
not observed in aliphatic region of spectrum) d 170.2, 150.0,
148.6, 146.4, 130.9, 128.0, 121.9, 119.3, 116.5, 111.9, 46.5, 46.4 (br);
HRMS Calculated 297.1710 (M+ + H) for C17H21N4O, found
297.1709.
2-[(4-Ethyl-1-piperazinyl)carbonyl]-N-(4-pyridinylmethyl)
aniline 19b
Obtained as a yellow solid; yield 45 %; mp 142–144 °C; 1H NMR
(300 MHz, CDCl3) d 8.54–8.52 (m, 2H), 7.27 (d, J = 5.9 Hz, 2H,),
7.18–7.10 (m, 2H), 6.68 (t, J = 5.9 Hz, 1H), 6.47 (d, J = 9.0 Hz, 1H),
5.78 (br t, J = 6.0 Hz, 1H), 4.38 (d, J = 6.0 Hz, 2H), 3.69 (br s, 4H),
2.50–2.42 (m, 6H), 1.11 (t, J = 6.0 Hz, 3H); 13C NMR (75 MHz,
CDCl3, one carbon not observed in aliphatic region) d 170.0,
150.0, 148.6, 146.4, 131.0, 128.1, 122.0, 119.2, 116.5, 111.9, 53.0, 52.3,
46.4, 11.9; HRMS Calculated 325.2023 (M+ + H) for C19H25N4O,
found 325.2021.
N-(4-Pyridinylmethyl)-2-{[4-(2-pyridinyl)-1-piperazinyl]
carbonyl}aniline 19c
Obtained as a yellow solid; yield 30 %; mp 62–64 °C; 1H NMR
(300 MHz, CDCl3) d 8.52 (d, J = 5.3 Hz, 2H), 8.20 (d, J = 3.7 Hz,
1H), 7.50–7.48 (m, 1H), 7.25 (d, J = 4.6 Hz, 2H), 7.20–7.14 (m, 2H),
6.73–6.61 (m, 3H), 6.49 (d, J = 8.2 Hz, 1H), 5.88–5.85 (m, 1H), 4.37
(d, J = 5.8 Hz, 2H), 3.79 (br s, 4H), 3.61 (br s, 4H); 13C NMR
(75 MHz, CDCl3, one aliphatic carbon not observed in spectrum)
d 170.5, 159.1, 150.0, 148.5, 148.1, 146.6, 137.7, 131.2, 128.2, 121.9,
118.9, 116.6, 114.1, 112.1, 107.3, 46.4, 45.7; HRMS Calculated
374.1981 (M+ + H) for C22H24N5O, found 374.1975.
N-(4-Pyridinylmethyl)-2-{[4-(4-pyridinyl)-1-piperazinyl]
carbonyl}aniline 19d
Obtained as a pale yellow solid; yield 34 %; mp 78–80 °C;
1H NMR (300 MHz, CDCl3) d 8.54 (br s, 2H), 8.33 (br s, 2H),
7.30–7.14 (br M, 4H), 6.70 (br s, 3H), 6.52 (d, J = 5.9 Hz, 1H), 5.96
(br s, 1H), 4.40 (br s, 2H), 3.83 (br s, 4H), 3.43 (br s, 4H); 13C NMR
(75 MHz, CDCl3, one aliphatic carbon not observed in spectrum)
d 170.6, 154.6, 150.4, 150.0, 148.4, 146.8, 131.5, 128.2, 121.9, 118.2,
116.5, 112.2, 108.7, 46.4, 46.3; HRMS Calculated 374.1981 (M+ +
H) for C22H24N5O, found 374.1983.
Activity Based Assay for IC50 Determination
IC50 determinations for EGFR wt, L858R and T790M/L858R
(purchased from Invitrogen: PV3872, PV4128, PV4879) were
measured with the HTRF KinEASE-TK assay from Cisbio accord-
ing to the manufacturer’s instructions. After 2 hours of pre-incu-
bation with the tested inhibitor and 50 nM of an artificial
biotinylated substrate peptide (TK-substrate), EGFR was allowed
to phosphorylate the latter by adding an ATP concentration
corresponding to its KM (30 µM for EGFR wt, 60 µM for EGFR
L858R and 30 µM for EGFR T790M/L858R, previously
determined using the same assay and EGFR constructs). After
completion of the reaction, an antiphosphotyrosine antibody
labelled with Europium cryptate and streptavidin labelled with
the fluorophore XL665 were added. The FRET between Euro-
pium cryptate and XL665 was measured to quantify the phos-
phorylation of the substrate peptide (Tecan Safire 2 plate reader,
excitation at 317 nm, readout at 620 nm -Eu-labelled antibody-
and 665 nm -XL665 labelled streptavidin- after 60 µs lag time).
The quotient of both intensities for reactions made with eight
different inhibitor concentrations (including no inhibitor) were
plotted against inhibitor concentrations and fit to a Hill
4-parameter equation to determine IC50 values (IDBS XLfit).
Each reaction was performed in duplicate, and at least three in-
dependent determinations of each IC50 were made.
According to the instructions given for EGFR testing, Akt1 wt
(120 pM, Millipore, Lot # D8MN034U-L), Akt2 wt (501 pM,
Invitrogen, Lot # PV3184_28770N) and DPH-Akt1 (Millipore,
Lot # 1600485-E), respectively were pre-incubated with the
respective inhibitors (eight different concentrations) in a dark
wet chamber for 1 h at RT. The phosphorylation reaction was
started by adding both ATP (50 µM for Akt1, 65 µM for both Akt 2
and DPH-Akt1) and STK-substrate 3 (250 nM for Akt1, 300 nM for
both Akt2 and DPH-Akt1). After incubation for 45 min (Akt 1),
20 min (Akt2) or 17 min (DPH-Akt1), respectively the reaction
was stopped and further incubated for 1 h at RT. Each well was
excited at 317 nm and emission was measured at 620 nm and
665 nm with a 60 µs delay using a Tecan infinite M1000 plate reader.
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Figure S1. Compounds 14a–l, 16, 18a-f and 19a & b tested on Abl T315I at 10 µM compound 
concentrations. A) Final emission ratios (Em665/Em620) determined for the respective compounds and 
controls. B) Normalized inhibition rates with respect to DMSO (100%) and Staurosporine (0%). 
 
 
Abl T315I (0.3 ng/well), purchased from Invitrogen (Lot#39639B, PV3866), was measured with the 
KinEASE-TK assay from Cisbio according to the manufacturer’s instructions. A biotinylated poly-Glu-
Tyr substrate peptide was phosphorylated and after completion of the reaction, an anti-phosphotyrosine 
antibody labeled with europium cryptate and streptavidin labeled with the fluorophore XL665 were added. 
FRET between europium cryptate and XL665 was measured to quantify the phosphorylation of the 
substrate peptide. ATP concentrations were set at the KM value (6 µM) and 250 nM TK-substrate were 
used. Kinase and inhibitor were preincubated for 30 min before the reaction was started by addition of 
ATP and substrate peptide. A Tecan infinite M1000 plate reader was used to measure the fluorescence of 
the samples at 620 nm (Eu-labeled antibody) and 665 nm (XL665 labeled streptavidin) 60 µs after 
excitation at 317 nm. The experiment was performed in duplicates using plain DMSO as negative control 
(100% remaining activity) and 10 µM Staurosporine as positive control (0% remaining activity). 
1 
Figure S2. Profiling of 14a at 10 µM compound concentration. 
 
2 
Figure S3. Profiling of 14h at 10 µM concentration. 
3 
14a and 14h were tested on 95 kinases at 10 µM concentrations using a radiometric (33P-γ-ATP) 
filter-binding assay conducted at the MRC Protein Phosphorylation Unit of the University of 
Dundee (http://www.kinase-screen.mrc.ac.uk/). ATP concentrations were chosen individually for 
each kinase to be at their respective ATP-Km. The remaining activity of each kinase was 
normalized and is represented in %. 
  
4 
Figure S4. Table containing testing of “library 1” (compounds 14a-l) and “library 2” 
(compounds 18a-f and 19a-d) against kinases Akt1 and Akt2. [n.i. = no inhibition up to 100 µM. 
All experiments were conducted in duplicate in three independent measurements (n = 3)]. 
 
structure name no 
% activity @ 100 µM IC50 / µM
Akt1 
ΔPH-
Akt1 
Akt2 Akt1 
ΔPH-
Akt1 
Akt2 
MeO
MeO NH2
N
H
O
Br
WvO-
1b 
14a 79 ± 8 102 ± 8 128 ± 9 n.i.  n.i. 
MeO
MeO NH2
N
H
O
WvO-
1c 
14b 82 ± 13 109 ± 11 120 ± 14    
MeO
MeO NH2
N
H
O
Cl
F
WvO-
2b 
14c 72 ± 7 112 ± 10 120 ± 5 n.i. n.i. n.i. 
MeO
MeO NH2
N
H
O
F
 
WvO-
2c 
14d 101 ± 25 108 ± 11 123 ± 2    
MeO
MeO NH2
N
H
O
OMe
OMe
WvO-
3b 
14e 104 ± 13 110 ± 13 130 ± 10 n.i.  n.i. 
MeO
MeO NH2
N
H
O
 
WvO-
4b 
14f 69 ± 7 104 ± 8 128 ± 12 n.i.  n.i. 
MeO
MeO NH2
N
O
N
N
N
WvO-
5b 
14g 101 ± 11 102 ± 4 127 ± 3 n.i.  n.i. 
MeO
MeO NH2
N
O
N
Cl
Cl
 
WvO-
10b 
14h 85 ± 19 101 ± 7 109 ± 2 n.i.  n.i. 
5 
MeO
MeO NH2
N
O
N
 
WvO-
8b 
14i 85 ± 19 106 ± 12 122 ± 5    
MeO
MeO NH2
N
O
N
O  
WvO-
6b 
14j 83 ± 12 110 ± 4 122 ± 1  n.i.  
MeO
MeO NH2
N
O
N
Ph WvO-
9b 
14k 80 ± 19 100 ± 15 125 ± 5 n.i.  n.i. 
WvO-
11b 
14l 93 ± 18 103 ± 11 122 ± 12    
         
WvO-
HFK1 
16 92 ± 13 105 ± 8 126 ± 1    
WvO-
SC3 
18a 100 ± 11 89 ± 17 128 ± 22    
 
WvO-
SC2 
18b 109 ± 13 102 ± 4 108 ± 13 n.i.  n.i. 
 
WvO-
HFK3 
18c 91 ± 14 86 ± 15 134 ± 7 n.i.  n.i. 
6 
WvO-
HFK4 
18d 66 ± 6 72 ± 12 95 ± 8 n.i. n.i. n.i. 
 
WvO-
HFK5 
18e 83 ± 0,5 106 ± 3 151 ± 5    
 
 
WvO-
HFK13 
18f 93 ± 5 101 ± 4 89 ± 4 n.i.  n.i. 
 
WvO-
SC4 
19a 113 ± 8 103 ± 7 98 ± 4 n.i.  n.i. 
WvO-
SC5 
19b 90 ± 16 103 ± 2 87 ± 1 n.i.  n.i. 
WvO-
HFK4-
2 
19c 100 ± 19 104 ± 10 
 
n.i.  n.i. 
7 
 WvO-
HFK4-
1 
19d 81 ± 20 105 ± 6 
 
n.i.  n.i. 
 
        
 
 
8 
